Skip to main content
Premium Trial:

Request an Annual Quote

Alacris Attains Illumina CSPro Certification for NGS

NEW YORK (GenomeWeb News) – Alacris Theranostics today said that is has gained Illumina CSPro certification for next-generation sequencing.

Illumina CSPro is a collaborative service provider partnership aimed at providing high quality data for genetic analysis applications, and applicants undergo a two-phase process that includes minimum data generation, data certification, and an onsite audit of the facility and processes.

Based in Berlin, Alacris specializes in personalized medicine for cancer patient diagnosis, treatment, and stratification, it said on its website. It uses a systems biology approach, called ModCell, developed at the Max Planck Institute for Molecular Genetics and licensed to Alacris. The approach is based on next-generation sequencing to provide information about the genome and transcriptome, and incorporates kinetic pathway information, and mutation and drug databases.

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.